Due to the insensitivity to conventional chemotherapy, gemcitabine administration is suppressed by the peritumor stroma and pancreatic cancer patients with low pancreatic hENT1 levels exhibit a significantly lower response to gemcitabine. The gene discussed is SLC29A1; the disease is pancreatic neoplasm.